COPD study initiation expands WIN378 development into a second major respiratory diseaseWIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in ...
Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...
Use of biologics significantly reduced exacerbations and hospitalizations in adults with chronic obstructive pulmonary disease (COPD) and overlapping type 2 asthma inflammation, based on data from a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with moderate or severe COPD receiving dupilumab ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with moderate or severe COPD receiving 300 mg of ...
Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according to a study presented at CHEST 2024, the ...
These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...
The natriuretic peptides, specifically brain natriuretic peptide (BNP), are the most specific and applicable laboratory tests available to establish fluid overload associated with HF. 9 BNP is ...
"The key finding as a clinician is to recognize that severe COPD patients have heterogeneity in terms of biological processes, which likely explains variable clinical courses and responses to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results